Foresite Capital Management VI LLC
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 15, 2025), Foresite Capital Management VI LLC reported 14 stock positions worth $182.5 million. Its top holding was CG Oncology (CGON) at 29.8% of the portfolio, followed by Alumis (ALMS, 14.1%) and Centessa Pharmaceuticals (CNTA, 9.9%). Its holdings were unchanged from Q4 2024.
- Most Recent 13F
- Q2 2026
- Location
- WEST HOLLYWOOD, CA
- CIK
- 0002013341
- Portfolio Value
- $182.5M (Q1 2025)
- SEC Filing
- 0001104659-25-049404 ↗ filed May 15, 2025
Holdings Value
Holdings 14 stocks · $182.5M
| CGON CG Oncology Inc. | 29.80% | 2,221,474 | $54.4M | No change |
| ALMS Alumis Inc. | 14.14% | 4,202,670 | $25.8M | No change |
| CNTA Centessa Pharmaceuticals Ltd. | 9.87% | 1,253,379 | $18.0M | No change |
| RAPT THERAPEUTICS INC | 8.35% | 12,500,000 | $15.3M | No change |
| AKRO Akero Therapeutics Inc. | 8.09% | 365,000 | $14.8M | No change |
| EWTX Edgewise Therapeutics Inc. | 7.05% | 585,000 | $12.9M | No change |
| BCAX Bicara Therapeutics Inc. | 6.78% | 950,000 | $12.4M | No change |
| GPCR Structure Therapeutics Inc. | 3.98% | 420,000 | $7.3M | No change |
| ALLO Allogene Therapeutics Inc. | 2.76% | 3,448,275 | $5.0M | No change |
| CRVS Corvus Pharmaceuticals Inc. | 2.75% | 1,581,233 | $5.0M | No change |
| CGEM Cullinan Therapeutics Inc. | 2.63% | 634,558 | $4.8M | No change |
| KYMR Kymera Therapeutics Inc. | 2.19% | 146,332 | $4.0M | No change |
| CASIF Casi Pharmaceuticals Inc. | 1.57% | 1,329,383 | $2.9M | No change |
| VRDN Viridian Therapeutics Inc. | 0.01% | 1,974 | $27K | No change |
Portfolio Sells Q4 2024 → Q1 2025
| None this quarter. | |||
Portfolio Buys Q4 2024 → Q1 2025
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 23 | $642.6M | CGON, ALMS, SPTX, DNLI, CLDX |
| Q1 2026 | 17 | $460.3M | CGON, ALMS, CNTA, CRVS, DNLI |
| Q4 2025 | 12 | $330.8M | CGON, RAPT, ALMS, CNTA, VSTM |
| Q3 2025 | 12 | $258.9M | CGON, RAPT, CNTA, VSTM, ALMS |
| Q2 2025 | 20 | $177.9M | CGON, CNTA, AKRO, ALMS, RAPT |
| Q1 2025 | 14 | $182.5M | CGON, ALMS, CNTA, RAPT THERAPEUTICS INC, AKRO |
| Q4 2024 | 14 | $224.4M | CGON, ALMS, CNTA, RAPT THERAPEUTICS INC, BCAX |